Fermenta Biotech Ltd
Fermenta Biotech Q4 FY26: Revenue ₹547.8 Cr, PAT ₹18.6 Cr
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY - Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY - Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY - FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY - Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY - Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY - Green Chemistry Sales: ₹16 crore, up 126% YoY - Real estate value unlocking declined significantly (INR 45 crore in FY25 vs INR 2 crore in FY26) impacting headline figures - No explicit forward-looking revenue or volume guidance stated in the presentation. Q4/FY26 EBITDA: ₹25.1 crore, down 39% YoY (Page 5) - Q4/FY26 Profit after Tax (PAT): ₹18.6 crore, down 44% YoY (Page 5) - Operating margin: EBITDA margin held at 22.3% (Page 5) - Revenue for Q4/
From Fermenta Biotech Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY
- Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY
- Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY
- FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY
- Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY
- Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY
- Green Chemistry Sales: ₹16 crore, up 126% YoY
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for FY26 was INR 30 crore, up from INR 22 crore in FY25, focused on capacity readiness (Page 11).
- Investing cash flow showed a net outflow of INR 43 crore in FY26, mainly on capacity additions (Page 11).
- Capacity expansion driver mentioned: employee cost increased to 16% in FY26 from 15% in FY25, indicating headcount addition due to capacity growth (Page 12).
- Manufacturing footprint includes multiple plants (Kullu, Dahej, Thane, Pennepalli) with focus on enzymes, APIs, and customized premix plant (Page 16).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Fermenta Biotech Ltd Q4 FY26 results?
Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY - Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY - Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY - FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY - Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY - Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY - Green Chemistry Sales: ₹16 crore, up 126% YoY - Real estate value unlocking declined significantly (INR 45 crore in FY25 vs INR 2 crore in FY26) impacting headline figures - No explicit forward-looking revenue or volume guidance stated in the presentation. Q4/FY26 EBITDA: ₹25.1 crore, down 39% YoY (Page 5) - Q4/FY26 Profit after Tax (PAT): ₹18.6 crore, down 44% YoY (Page 5) - Operating margin: EBITDA margin held at 22.3% (Page 5) - Revenue for Q4/
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
Capex for FY26 was INR 30 crore, up from INR 22 crore in FY25, focused on capacity readiness (Page 11).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.